Zobrazeno 1 - 10
of 236
pro vyhledávání: '"Filippo de Marinis"'
Autor:
Lorinda Simms, Shehkar Patil, David R. Gandara, Anders Mellemgaard, Raghunadharao Digumarti, Bonne Biesma, Johan Vansteenkiste, Mauro Zukin, Joachim von Pawel, Katherine P. Sugarman, Keunchil Park, Christian Manegold, Filippo de Marinis, Tuncay Göksel, Janusz Rolski, Piotr Serwatowski, Jin S. Lee, Giorgio V. Scagliotti, Ulrich Gatzemeier, Purvish M. Parikh
Publikováno v:
Journal of Clinical Oncology. 41:2458-2466
PURPOSE Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non–small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting. PATIENTS AND METHODS
Autor:
Konstantin Laktionov, Chong-Jen Yu, Kye Young Lee, Frances A. Shepherd, Roy S. Herbst, Filippo de Marinis, Yi-Long Wu, Zhijie Wang, Jonathan W. Goldman, Charuwan Akewanlop, Christian Grohé, Terufumi Kato, Thomas John, Huu Vinh Vu, Margarita Majem, Laura Bonanno, Ajlan Atasoy, Masahiro Tsuboi, Lingmin Zeng, Sang-We Kim, Shun Lu, Manuel Domine
Publikováno v:
Journal of Thoracic Oncology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Introduction: Adjuvant chemotherapy is recommended in patients with resected stages II to IIIA (and select IB) NSCLC; however, recurrence rates are high. In the phase 3 ADAURA study (NCT02511106), osimertinib was found to have a clinically meaningful
Autor:
Todd M. Bauer, Julien Mazieres, Anna Polli, Benjamin Solomon, Enriqueta Felip, Gerson Peltz, Alice T. Shaw, Filippo de Marinis, Tony Mok, Geoffrey Liu, Yasushi Goto, A.M. Calella, Holger Thurm, Dong Wan Kim
Publikováno v:
Future Oncology. 17:4649-4656
This is a summary of a research study (known as a clinical trial) called CROWN. The study tested two medicines called lorlatinib and crizotinib in participants with untreated non-small cell lung cancer that had spread to other parts of their body. Al
Autor:
Sarah M. Paul, Filippo de Marinis, Rafal Dziadziuszko, David S. Shames, Shirish M. Gadgeel, Hye Ryun Kim, Todd Riehl, Natasha B. Leighl, Osvaldo Arén Frontera, Ernest Nadal, Mark Yan, Jorge Arturo Alatorre-Alexander, Daniel Shao-Weng Tan, Ji Youn Han, Maurice Pérol, Dae Ho Lee, Rajesh Patel, Simonetta Mocci, Zoe June Assaf, M. Mathisen, Erica B. Schleifman, Tony Mok, Solange Peters, Virote Sriuranpong, Gilberto de Castro Junior
Publikováno v:
Journal of Thoracic Oncology. 16:2040-2050
Introduction The Blood First Assay Screening Trial is an ongoing open-label, multicohort study, prospectively evaluating the relationship between blood-based next-generation sequencing (NGS) detection of actionable genetic alterations and activity of
Autor:
Filippo de Marinis, Francesca Porta, Elena Guerini-Rocco, Carmine Valenza, Giuseppe Curigliano, Chiara Catania, Alessandra Rappa, Massimo Barberis, Giuseppe Viale
Publikováno v:
Current Oncology, Vol 28, Iss 292, Pp 3384-3392 (2021)
Current Oncology
Current Oncology
We present a case of a woman with epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma who received gefitinib for 2 years and obtained a partial response. The patient then developed liver metastasis and a breast lesion, displaying high
Publikováno v:
The Thoracic and Cardiovascular Surgeon. 70:273-276
This case series aimed to analyze the outcomes of patients referred for salvage pulmonary resections after treatment with chemotherapy and immunotherapy for previously metastatic or unresectable tumors.From October 2016, after multidisciplinary board
Autor:
Paolo Tarantino, Ilaria Attili, Filippo de Marinis, Giuseppe Curigliano, Valeria Stati, Antonio Passaro
Publikováno v:
Lung Cancer. 154:151-160
The adoption of Immune checkpoint inhibitors (ICIs) allowed the achievement of impressive long-term survival results in non-small cell lung cancer (NSCLC), but most patients develop resistance to ICI treatment over time. Resistance to ICIs is mediate
Autor:
Yi-Long Wu, Ying Cheng, Jianying Zhou, Shun Lu, Yiping Zhang, Jun Zhao, Dong-Wan Kim, Ross Andrew Soo, Sang-We Kim, Hongming Pan, Yuh-Min Chen, Chih-Feng Chian, Xiaoqing Liu, Daniel Shao Weng Tan, Rolf Bruns, Josef Straub, Andreas Johne, Jürgen Scheele, Keunchil Park, James Chih-Hsin Yang, Zhe Liu, Xi Chen, Mengzhao Wang, Shiying Yu, Helong Zhang, Jian Fang, Wei Li, Chih-Hsin Yang, Gee-Chen Chang, Te-Chun Hsia, Cheng-Ta Yang, Chin-Chou Wang, Byoung Chul Cho, Ki Hyeong Lee, Young-Chul Kim, Ho Jung An, In Sook Woo, Jae Yong Cho, Sang Won Shin, Jong-Seok Lee, Joo-Hang Kim, Seung Soo Yoo, Terufumi Kato, Naofumi Shinagawa, Shao Weng Daniel Tan, Lynette Si-Mien Ngo, Kananathan Ratnavelu, Azura Rozila Ahmad, Chong Kin Liam, Filippo de Marinis, Pierfrancesco Tassone, Amelia Insa Molla, Antonio Calles Blanco, Martin Emilio Lazaro Quintela, Enriqueta Felip Font, Anne-Marie Dingemans, Lynne Bui
Publikováno v:
The Lancet Respiratory Medicine. 8:1132-1143
Summary Background We evaluated the efficacy and safety of tepotinib, a potent and highly selective oral MET inhibitor, plus gefitinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) with MET overexp
Autor:
Konstantin Laktionov, Yi-Long Wu, Shun Lu, Kye-Young Lee, Thomas John, Terufumi Kato, Masahiro Tsuboi, Chong-Jen Yu, Jonathan W. Goldman, Manuel Domine, Yuri Rukazenkov, C. Grohe, Lingmin Zeng, Laura Bonanno, Jie He, Huu-Vinh Vu, Sang-We Kim, Frances A. Shepherd, Filippo de Marinis, Margarita Majem, Ajlan Atasoy, Rachel Hodge, Roy S. Herbst, Charuwan Akewanlop
Publikováno v:
New England Journal of Medicine. 383:1711-1723
BACKGROUND: Osimertinib is standard-of-care therapy for previously untreated epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). The efficacy and safety of osimertinib as adjuvant therapy are unknown
Autor:
Niels Reinmuth, Simonetta Mocci, Filippo de Marinis, Roy S. Herbst, David R. Spigel, Kimberly Komatsubara, Hiroshi Kuriki, Jacek Jassem, Alan Sandler, Mustafa Ozguroglu, Wei Zou, Alain Vergnenegre, Mark McCleland, Giuseppe Giaccone, Enriqueta Felip, X. Wen, Masahiro Morise, Carlos H. Barrios, Yu Deng, Z. Andric, Sarayut Lucien Geater, Ida Enquist
Publikováno v:
New England Journal of Medicine. 383:1328-1339
Background The efficacy and safety of the anti–programmed death ligand 1 (PD-L1) monoclonal antibody atezolizumab, as compared with those of platinum-based chemotherapy, as first-line trea...